CSat Investment Advisory L.P. Has $1.37 Million Stake in Humana Inc (HUM)
CSat Investment Advisory L.P. grew its stake in Humana Inc (NYSE:HUM) by 15.4% during the fourth quarter, HoldingsChannel.com reports. The firm owned 4,777 shares of the insurance provider’s stock after buying an additional 638 shares during the period. Humana makes up about 0.8% of CSat Investment Advisory L.P.’s holdings, making the stock its 28th biggest holding. CSat Investment Advisory L.P.’s holdings in Humana were worth $1,369,000 at the end of the most recent quarter.
Several other hedge funds also recently bought and sold shares of the company. FMR LLC lifted its stake in shares of Humana by 1.4% in the 3rd quarter. FMR LLC now owns 12,379,797 shares of the insurance provider’s stock valued at $4,190,809,000 after purchasing an additional 167,283 shares during the period. BlackRock Inc. lifted its stake in shares of Humana by 1.2% in the 3rd quarter. BlackRock Inc. now owns 12,311,736 shares of the insurance provider’s stock valued at $4,167,767,000 after purchasing an additional 140,731 shares during the period. Vanguard Group Inc lifted its stake in shares of Humana by 1.4% in the 3rd quarter. Vanguard Group Inc now owns 10,104,225 shares of the insurance provider’s stock valued at $3,420,482,000 after purchasing an additional 140,864 shares during the period. Capital International Investors lifted its stake in shares of Humana by 3,030.3% in the 3rd quarter. Capital International Investors now owns 8,217,296 shares of the insurance provider’s stock valued at $2,781,719,000 after purchasing an additional 7,954,786 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in shares of Humana by 14.1% in the 3rd quarter. Renaissance Technologies LLC now owns 3,174,800 shares of the insurance provider’s stock valued at $1,074,733,000 after purchasing an additional 391,300 shares during the period. 93.28% of the stock is currently owned by institutional investors.
HUM has been the topic of a number of analyst reports. Zacks Investment Research raised Humana from a “hold” rating to a “buy” rating and set a $327.00 price target on the stock in a research note on Thursday, December 20th. Barclays reissued a “buy” rating and issued a $351.00 price target on shares of Humana in a research note on Sunday, January 6th. Citigroup cut their price target on Humana from $397.00 to $362.00 and set a “buy” rating on the stock in a research note on Thursday, February 7th. ValuEngine downgraded Humana from a “buy” rating to a “hold” rating in a research note on Friday, December 7th. Finally, Cantor Fitzgerald reissued a “hold” rating and issued a $325.00 price target on shares of Humana in a research note on Wednesday, January 2nd. Five research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Humana currently has an average rating of “Buy” and a consensus target price of $355.06.
Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, February 6th. The insurance provider reported $2.65 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.53 by $0.12. The business had revenue of $14.17 billion for the quarter, compared to the consensus estimate of $14.04 billion. Humana had a return on equity of 19.64% and a net margin of 2.96%. The firm’s revenue was up 7.4% compared to the same quarter last year. During the same quarter last year, the business posted $2.06 EPS. On average, analysts expect that Humana Inc will post 17.49 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Friday, March 29th will be paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.80%. The ex-dividend date of this dividend is Thursday, March 28th. This is an increase from Humana’s previous quarterly dividend of $0.50. Humana’s dividend payout ratio (DPR) is presently 6.87%.
In other Humana news, insider Roy A. Beveridge sold 8,278 shares of the stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $307.16, for a total transaction of $2,542,670.48. Following the completion of the transaction, the insider now owns 12,409 shares in the company, valued at approximately $3,811,548.44. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Christopher H. Hunter sold 15,586 shares of the stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $305.24, for a total value of $4,757,470.64. Following the transaction, the insider now owns 28,100 shares of the company’s stock, valued at approximately $8,577,244. The disclosure for this sale can be found here. Company insiders own 0.54% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “CSat Investment Advisory L.P. Has $1.37 Million Stake in Humana Inc (HUM)” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2019/03/21/csat-investment-advisory-l-p-has-1-37-million-stake-in-humana-inc-hum.html.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Read More: Is the QQQ ETF safe?
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.